Cancer Panel From Blood of Lung Cancer Patients (CAPABLE)
Clinical Validity of Oncogenic Driver Genes Detected From Circulating Tumor DNA in Blood of Lung Cancer Patients
Sponsor: MACROGEN
A observational or N/A phase clinical study on Non Small Cell Lung Cancer Metastatic and Non Small Cell Lung Cancer Recurrent, this trial is ongoing. The trial is conducted by MACROGEN and has accumulated 11 data snapshots since 2017. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
11 versions recorded-
Sep 2025 — Present [monthly]
Unknown
-
Sep 2024 — Sep 2025 [monthly]
Unknown
-
Jul 2024 — Sep 2024 [monthly]
Unknown
Status: Unknown Status → Unknown
-
Dec 2021 — Jul 2024 [monthly]
Unknown Status
-
Feb 2021 — Dec 2021 [monthly]
Unknown Status
Status: Active Not Recruiting → Unknown Status
▶ Show 6 earlier versions
-
Jan 2021 — Feb 2021 [monthly]
Active Not Recruiting
-
Nov 2020 — Jan 2021 [monthly]
Active Not Recruiting
-
Feb 2019 — Nov 2020 [monthly]
Active Not Recruiting
Status: Recruiting → Active Not Recruiting
-
May 2018 — Feb 2019 [monthly]
Recruiting
-
Apr 2018 — May 2018 [monthly]
Recruiting
Phase: NA → None
-
Aug 2017 — Apr 2018 [monthly]
Recruiting NA
First recorded
Mar 2017
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- MACROGEN
- Seoul National University Hospital
For direct contact, visit the study record on ClinicalTrials.gov .